Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10966415 | Vaccine | 2013 | 9 Pages |
Abstract
Pneumococcal polysaccharide vaccines have been used to elicit a protective anti-pneumococcal polysaccharide antibody response against Streptococcus pneumoniae in healthy individuals. Identifying human B cells which respond to T-cell independent type-2 antigens, such as pneumococcal polysaccharides, has been challenging. We employed pneumococcal polysaccharides directly conjugated to fluorophores in conjunction with flow cytometry to identify the phenotype of B cells that respond to pneumococcal polysaccharide vaccination. We have previously identified that the majority of pneumococcal polysaccharide-selected cells responding to vaccination are CD27+IgM+ (IgM+ memory) cells. In this study, we further characterized pneumococcal polysaccharide-selected cells in the peripheral blood to better identify how the various B cell phenotypes responded 7 and 30 days post-immunization. We show that 7 days post-immunization the majority of pneumococcal polysaccharide-selected IgM+ memory cells (PPS14+ 56.5%, PPS23F+ 63.8%) were CD19+CD20+CD27+IgM+CD43+CD5+/âCD70â, which was significantly increased compared to pre-immunization levels. This phenotype is in alignment with recent publications describing human B-1 cells. PPS-responsive B cells receded to pre-immunization levels by day-30. These findings suggest that this B-1 like cell population plays an important role in early responses to S. pneumoniae infection and possibly other T-cell independent type-2 antigens in humans
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
David J. Leggat, Noor M. Khaskhely, Anita S. Iyer, Jason Mosakowski, Rebecca S. Thompson, John D. Weinandy, M.A. Julie Westerink,